The National Institute of Oncology in Gliwice has launched a pioneering clinical study using a novel radiotracer for immuno-PET imaging. As one of the first initiatives of its kind in the region, the project marks a meaningful step forward for advanced diagnostics in Central and Eastern Europe.
At Axcellant, we closely follow developments in the field of nuclear medicine and molecular imaging, particularly where they intersect with clinical research. Imaging-based trials, such as this one, are not only scientifically ambitious but also logistically complex. Successfully executing such studies requires a deep understanding of regulatory frameworks, robust imaging infrastructure, and tight coordination between interdisciplinary teams.
Poland’s growing activity in this space is an encouraging sign for sponsors looking for experienced research partners beyond traditional Western hubs. As a CRO with strong expertise in imaging-supported clinical trials, we welcome this progress and look forward to supporting more innovation in the region.
Read the full article (in Polish) here.
Axcellant will participate in the Annual Congress of the European Association of Nuclear Medicine (EANM 2026), taking place from 17…
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…
Copyright @ 2026 Axcellant